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We compared the clinical efficacy and safety of two doses of ropivacaine for spinal anesthesia in Chinese
patients undergoing lower limb and lower abdominal surgery. In this randomized, open-label study,
40 patients were divided into two groups: group A received 3.5 mL (26.25 mg) of 0.75% glucose-free
ropivacaine, and group B received 4.5 mL (33.75 mg). Sensory and motor blocks were assessed during
and after surgery through to complete recovery. Seven standard measurements were taken: time to onset
of sensory blocks; maximum sensory cephalad spread; time to maximum sensory block; maximum number
of blocked segments; duration of sensory block at L3; time to onset of complete motor block; and duration
until complete motor block recovery. Vital signs and any adverse effects related to spinal anesthesia were
also recorded. No significant differences were found between the two groups: time to onset of sensory
block at L3 in group A vs B (2.1 ± 9.6 vs 1.7 ±  7.3 minutes), maximum cephalad spread [T4–5 (C3–T11)
vs T4 (C3–T8)], maximum number of blocked segments (18.0 ± 3.4 vs 19.8 ± 3.7), time to maximum sensory
block (34.0 ±  22.9 vs 26.8 ±  17.9 minutes), duration of sensory block at L3 (251.2 ±  34.7 vs 277.3 ±
51.1 minutes), time to onset of complete motor block (13.4 ± 6.4 vs 10.3 ± 3.4 minutes), and time for complete
recovery from motor block (264 ±  52.1 vs 292.5 ±  64.5 minutes). No significant differences in global
hemodynamic changes were found during and after the operation. While shivering was more frequent
in group B during the operation, the difference was not significant. Otherwise, there were no differences
in adverse effects during and after surgery. We conclude that both doses of 0.75% glucose-free ropivacaine,
26.25 mg (3.5 mL) and 33.75 mg (4.5 mL), have the same efficacy and safety in Chinese patients undergoing
spinal anesthesia for lower limb and lower abdominal surgery.
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Ropivacaine, the S-(-)-enantiomer of 1-propyl-2,6-pipecolo-
xylidide, is a new amino-amide local anesthetic, structurally
related to bupivacaine and mepivacaine [1]. It is an effective
local anesthetic with a long duration of action when given
epidurally [2–5]. Sensory block characteristics after epidural
administration of ropivacaine 0.5% are similar to those of
bupivacaine 0.5% [3]. However, ropivacaine 0.5% provides
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less potent motor block than bupivacaine 0.5% [6].
There are, however, few reports on ropivacaine as a
local spinal anesthetic in humans. In 1994, van Kleef et al
concluded that subarachnoid injection of glucose-free ro-
pivacaine solutions resulted in a variable spread of anal-
gesia, mostly accompanied by a good quality of motor
block with the 0.75% solution but not the 0.5% solution
[6]. In vivo studies in dogs and mice have also indicated
that, at equal drug concentrations, spinally administrat-
ed ropivacaine is less potent and has a shorter duration
of motor block than bupivacaine [1,7].
In recent years, there has been more research on the
use of ropivacaine for spinal anesthesia in obstetric [8–
10] and non-obstetric patients [6,11–15]. Most of these
studies have concluded that ropivacaine is less potent
than bupivacaine [8,11–14].
There are few data on adequate spinal anesthesia
dosing with 0.75% glucose-free ropivacaine in Chinese
patients. Our previous studies showed that two doses of
0.75% glucose-free ropivacaine, 18.75 mg (2.5 mL) and
22.5 mg (3 mL), provided the same efficacy and safety in
patients undergoing spinal anesthesia for cesarean sec-
tion [16]. As no previous studies have assessed the effects
of different doses of ropivacaine for lower abdominal
and lower limb surgery, and because our pilot study
showed that doses of less than 5 mL ropivacaine could
provide safe spinal anesthesia for such procedures,
we compared the clinical efficacy and safety of 0.75%
glucose-free ropivacaine at two doses, 3.5 mL (26.25 mg)
and 4.5 mL (33.75 mg), as local anesthetic for spinal anes-
thesia in patients under-going lower limb and lower ab-
dominal surgery.
MATERIALS AND METHODS
Study design
This study was a randomized, open-label clinical trial of
0.75% ropivacaine for spinal anesthesia during lower
limb and lower abdominal surgery. According to our pi-
lot study and one previous report [16], doses between
3 mL and 5 mL (22.5–37.5 mg) are effective and safe, though
precisely which doses were not determined. We studied
two groups: group A was given 3.5 mL (26.25 mg) and
group B was given 4.5 mL (33.75 mg). The study protocol
was approved by the hospital’s research and ethics
committee, the investigation was fully explained to the
patients, and informed consent was obtained at the be-
ginning of the study. The study was continued through
to complete recovery from anesthesia.
Patients
The 40 patients enrolled in this study were between 18 and
60 years of age and had American Society of Anesthesio-
logists (ASA) physical status P1 or P2, body weights
between 50 kg and 70 kg, and heights between 155 cm
and 170 cm. Patients were free of specific cardiovascular
or neurologic diseases and were scheduled for lower limb
or lower abdominal surgery with spinal anesthesia.
Medications and procedures
No premedication was given. Patients were prehydrated
before anesthesia and had standard monitoring, including
continuous electrocardiogram, pulse oximetry, and non-
invasive measurement of arterial blood pressure cycled
at 1-minute intervals. Local anesthetic for spinal anesthe-
sia was 0.75% ropivacaine glucose-free solution (Naro-
pin®; Astra AB, Södertälje, Sweden). Preliminary analy-
sis showed that the specific gravity at 37°C was 0.9991,
with a nearly isobaric relationship with cerebrospinal
fluid. After infusion of 250–500 mL of lactated Ringer’s
solution, each patient was placed in the lateral decubitus
position on the operating table. Local infiltration of the
skin with 2% lidocaine and dural puncture were per-
formed at the L3–4 lumbar vertebral interspace using a 27
gauge Quincke point spinal needle (Becton Dickinson,
San Jose, CA, USA). Needle position was confirmed by as-
piration and the free-flow of cerebrospinal fluid. Then,
3.5 mL or 4.5 mL of the anesthetic solution was injected
into patients in groups A and B, respectively. Full injec-
tion required between 15 and 20 seconds. After injection,
the patient was immediately placed in the supine posi-
tion. Systemic arterial blood pressure and heart rate
were monitored during induction and surgery and in
the recovery room. If the systolic blood pressure de-
creased by more than 25% of the pre-anesthetic value
or fell below 90 mmHg, ephedrine 10 mg was given
intravenously. Fentanyl 0.05–0.1 mg and/or midazolam
2–3 mg were given intravenously if adequate analgesia
was not achieved within 30 minutes of injection.
Assessment and evaluation
Before commencement of anesthesia, patients were in-
structed on the methods of sensory and motor assessments,
and baseline measurements were made. Analgesia (senso-
ry block) was assessed on both sides along the neck, arms,
trunk, legs, and perineum by testing loss of sensation to
cold using an alcohol sponge [11]. Motor block of the lower
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extremities was evaluated bilaterally using a modified
Bromage scale (0–3): 0 = full flexion of knees and feet; 1 =
just able to move knees; 2 = able to move feet only; 3 =
unable to move feet or knees. After spinal injection, we
assessed sensory loss and motor block scores every min-
ute during the first 5 minutes. During the first 30 minutes,
these values were re-assessed at 5-minute intervals.
Between 30 and 120 minutes, assessments were made at
15-minute intervals. Thereafter, they were made at 30-
minute intervals through to complete recovery. Seven
standard measurements were taken: time to onset of sen-
sory block, maximum sensory cephalad spread, time
to maximum sensory block, maximum number of blocked
segments, duration of sensory block at L3, time to onset
of complete motor block, and time to complete recovery.
The adequacy of surgical anesthesia was determined
on the basis of the patient’s subjective response to surgery
and the requirements for supplemental medication to
keep the patient comfortable and pain-free. Patients were
evaluated for possible adverse effects during surgery,
during the full period of anesthesia, and for 24 hours
after the surgical procedure.
Spinal anesthesia and assessments during anesthesia
and surgery were performed by the same attending anes-
thesiologist (the researcher). However, the assessment and
data collection after surgery and during the recovery period
were made by two well-trained nurses.
Statistical analyses
Data are presented as mean ± standard deviation, median
(range), or frequency, and were analyzed by the Mann-
Whitney U test (Wilcoxon rank sum test) and Chi-squared
test or Fisher’s exact test. A p value of less than 0.05 was
considered statistically significant.
RESULTS
All patients completed the study. Both groups had com-
parable demographic data, including age, height, weight,
and prehydration before spinal anesthesia. Characteris-
tics of patients and surgical procedures are summa-
rized in Tables 1 and 2, respectively.
In all patients, comparable levels of analgesia were ob-
tained (Table 3). The maximum cephalad spread of sensory
block was slightly greater in group B than in group A, and
the maximum number of blocked segments in group B
was two segments higher than in group A, but these dif-
ferences were not statistically significant (Figure 1). Al-
Table 1. Demographic data
Group A Group B       p
Number of patients 20 20
0.75% isobaric ropivacaine
Dose, mg 26.25 33.75
Volume, mL 3.5 4.5
Age, yr* 43.8 ±  14.8 43.3 ±  14.3 NS
Gender, male/female 11/9 16/4
Height, cm* 162.6 ±  5.1 163.9 ±  5.3 NS
Weight, kg* 61.9 ±  7.9 63.2 ±  5.2 NS
ASA physical status, n
P1 17 14
P2 3 6
Prehydration before spinal 197.5 ±  101 252.5 ±  129 NS
anesthesia, mL*
*Values are mean ±  standard deviation. NS = not significant;
ASA = American Society of Anesthesiologists.
Table 2. Surgical procedures
 Group A Group B
General surgery
Lower abdomen 2 8
Perineum, anus 5 1
Urology
TURP 1 0
Lower abdomen 3 4
Orthopedic surgery 7 5
(lower extremities)
Gynecologic surgery 2 2
(perineum, vagina, cervix)
TURP = transurethral resection of the prostate.
though the time to maximum sensory block was similar
in both groups, the onset time to complete motor block
was slightly lower in group B, and the duration of analge-
sia at L3 and the time for complete recovery from motor
block were slightly longer in group B than in group A,
but these differences were also not significant (Mann-
Whitney U-test) (Figure 2).
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There were also no significant differences in global
hemodynamic changes during and after surgery (Table 4).
However, at the beginning of anesthesia, one patient in each
group experienced transient hypotension, treated with total
ephedrine doses of 20 mg (Group A) and 22 mg (Group B).
Shivering was more frequently observed during surgery in
group B than in group A (Table 5). This difference, however,
was not significant. No other differences were noted in ad-
verse effects during and after surgery between and within
groups. One patient (5%) in group A and two (10%) in group
B did not achieve adequate analgesia within the first 30
minutes, so they received low-dose fentanyl (total dose:
Group A, 0.1 mg; Group B, 0.2 mg) and/or midazolam (total
dose: Group A, 5 mg; Group B, 9 mg), with no significant
differences between groups. All patients completed sur-
gery successfully without any residual neurologic symp-
toms or postdural puncture headache at follow-up.
DISCUSSION
The purpose of this study was to investigate the adequacy
Table 3. Characteristics of neural block after intrathecal 0.75% glucose-free ropivacaine solution 3.5 mL (26.25 mg) in group A
and 4.5 mL (33.75 mg) in group B
Group A Group B p*
Sensory block
Time to onset at L3, min 2.1 ±  9.6 1.7 ±  7.3 NS
Maximum cephalad spread or maximal sensory level, dermatome T4–5 (C3–T11) T4 (C3–T8) NS
Time to maximum cephalad spread or time to maximal level, min 34.0 ±  22.9 26.8 ±  17.9 NS
Maximum number of blocked segments 18.0 ±  3.4 19.8 ±  3.7 NS
Duration at L3 or time for regression to L3, min 251.2 ±  34.7 277.3 ±  51.1 NS
Motor block
Time to onset of complete block, min 13.4 ±  6.4 10.3 ±  3.4 NS
Patients with complete block, n 20 20 NS
Time to complete recovery or total duration, min 264 ±  52.1 292.5 ±  64.5 NS
*Mann-Whitney U-test (Wilcoxon rank sum test). Values are mean ± standard deviation. NS = no significant difference between groups.
Figure 1. Distribution of
the maximum cephalad
spread of sensory block.
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Figure 2. Intensity of motor blockade as evaluated using the modified Bromage scale: (A) group A; (B) group B.
Table 4. Hemodynamic changes before and after spinal anesthesia
Blood pressure, mmHg Heart rate, bpm
Pre-anesthesia Post-anesthesia Recovery Pre-anesthesia Post-anesthesia Recovery
15 min 30 min 60 min 120 min 15 min 30 min 60 min 120 min
Group A 132 ±  23/ 121 ±  17/ 114 ±  18/ 115 ±  20/ 111 ±  15/ 76 ±  13 70 ±  15 64 ±  12 63 ±  11 63 ±  11
73 ±  16 58 ±  17 58 ±  14 57 ±  11 62 ±  12
Group B 136 ±  19/ 123 ±  19/ 117 ±  22/ 113 ±  21/ 118 ±  21/ 79 ±  14 74 ±  15 67 ±  13 66 ±  11 69 ±  12
75 ±  15 60 ±  15 58 ±  15 56 ±  14 56 ±  17
Values are mean ± standard deviation. There were no significantly different changes in blood pressure or heart rate for the periods pre-anesthesia,
during anesthesia and recovery, between and within groups. Mann-Whitney U-test (Wilcoxon rank sum test).
of two different doses of 0.75% glucose-free ropivacaine,
26.25 mg in 3.5 mL vs 33.75 mg in 4.5 mL, and to compare
their relative anesthetic efficacy and safety during spinal
anesthesia in Chinese patients undergoing lower limb and
lower abdominal surgery. We found that both doses of
ropivacaine provided adequate anesthesia. Although no
significant difference was found between groups, possibly
due to the small difference in dose (1 mL), the higher dose
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had a slightly faster time to maximal sensory cephalad
spread and complete motor block, and slightly longer
sensory and motor regression (Table 3, Figures 1 and 2).
Previous studies found that better motor block was ob-
tained with 0.75% ropivacaine than 0.5% ropivacaine [6,11].
The optimal dosage of spinal anesthesia with plain or
isobaric ropivacaine for lower limb and lower abdominal
surgery is still unknown. van Kleef et al reported that 3 mL
of 0.5% (15 mg) glucose-free ropivacaine was suitable for
transurethral procedures or minor orthopedic surgery when
the degree of motor block was not of critical importance,
and 3 mL of 0.75% (22.5 mg) glucose-free ropivacaine
provided the most satisfactory conditions for lower limb
surgery of intermediate duration [6]. Wahedi et al also
concluded that a dose of 3 mL of 0.75% isobaric ropiva-
caine seemed to be suitable for gynecologic and uro-
logic operations [11]. However, Malinovsky et al report-
ed that 5 mL of 0.3% (15 mg) isobaric ropivacaine was in-
effective for endoscopic procedures of the lower urologic
tract compared to 10 mg of bupivacaine [14]. Previous
studies have shown that the equipotent ratio between
bupivacaine and ropivacaine is 3:2 with an isobaric so-
lution for knee arthroscopy [12], or 2:1 with a hyper-
baric solution in volunteers [13].
Analgesic spread with isobaric spinal ropivacaine is
reported to be widely variable [6,11–13], as it was in this
study, extending from segments C3 to T11. Although re-
cent studies have suggested that the addition of glucose
to spinal ropivacaine, a hyperbaric solution, improved
reliability and might enable a smaller dose to be used
[8,10,13,15], this addition resulted in faster times of onset
of and recovery from sensory and motor block, with a
higher incidence of hypotension in cesarean delivery
(67–100%) [8,10] and non-obstetric surgery (15–20%)
[15] compared to Wahedi et al’s study (5%) [11], Malinov-
sky et al’s study (40%) [14], and our study (5–10%) using
isobaric solution in non-obstetric procedures. Fortunate-
ly, all patients in our study obtained adequate analgesia
and complete motor block, and prolonged onset of block
allowed more time for hydration, reducing hypotension.
Some reports have concluded that, with hyperbaric so-
lutions, the rates of recovery from sensory and motor
block are faster than with plain/isobaric spinal ropiva-
caine in cesarean delivery [8,10] and non-obstetric sur-
gery [15], possibly suggesting that a hyperbaric solution
is suitable for use in ambulatory anesthesia and short-
duration anesthesia, such as cesarean delivery. The
prolonged sensory and motor block with plain/isobaric
spinal ropivacaine (0.75%) may provide good analgesia
for longer-duration surgery and reduce the use of peri-
operative analgesics [6].
Our findings of stable hemodynamics during sur-
gery and low incidences of inadequate analgesia (10–20%)
and other adverse effects such as postspinal headache are
in agreement with Gautier et al’s [12] and Khaw et al’s
results [10]. These factors would ordinarily suggest 0.75%
glucose-free spinal ropivacaine for anesthesia for lower
limb and lower abdominal surgery; however, because the
high variation in the spread of sensory block within groups
may affect anesthetic efficacy, further investigation is
needed.
In conclusion, we compared the effects of two different
doses of 0.75% glucose-free ropivacaine in spinal anes-
thesia for lower limb and lower abdominal surgery. We
Table 5. Adverse effects related to spinal anesthesia during surgery and the recovery period
Group A (n = 20) Group B (n = 20)
Surgery Recovery period Surgery Recovery period
Shivering 3 3 7 2
Nausea 1 2 3 1
Vomiting 1 2 1 0
Hypotension (↓ > 25%) 1 0 2 1
Pain (inadequate analgesia) 1 0 2 0
Restlessness 0 0 1 0
Bradycardia 1 0 3 0
Dyspnea 0 0 2 0
Backache 0 0 0 1
No significant difference between groups; Chi-squared test/Fisher’s exact test.
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found that 26.25 mg (3.5 mL) and 33.75 mg (4.5 mL) were
equally effective and safe in Chinese patients under-
going spinal anesthesia for lower limb and lower ab-
dominal surgery.
ACKNOWLEDGMENTS
The authors thank Ms. Kuan-Yun Chi and Ms. Ellen C.Y.
Lan for their assistance in follow-up and data collection, the
staff of the Department of Anesthesiology, St. Martin De
Porres Hospital, for their cooperation, Professor James F.
Steed for editing our English, and AstraZeneca (Taiwan)
for providing the ropivacaine.
REFERENCES
1. Akerman B, Hellberg B, Trossvik C. Primary evaluation of
the local anaesthetic properties of the amino amide agent
ropivacaine (LEA 103). Acta Anaesthesiol Scand 1988;32:571–8.
2. Concepcion M, Arthur GR, Steele SM, et al. A new local anes-
thetic, ropivacaine. Its epidural effects in humans. Anesth
Analg 1990;70:80–5.
3. Brockway MS, Bannister J, McClure JH, et al. Comparison of
extradural ropivacaine and bupivacaine. Br J Anaesth 1991;
66:31–7.
4. Katz JA, Knarr D, Bridenbaugh PO. A double-blind compari-
son of 0.5% bupivacaine and 0.75% ropivacaine administered
epidurally in humans. Reg Anesth 1990;15:250–2.
5. Zaric D, Axelsson K, Nydahl PA, et al. Sensory and motor
blockade during epidural analgesia with 1%, 0.75% and 0.5%
ropivacaine – a double-blind study. Anesth Analg 1991;72:
509–15.
6. van Kleef JW, Veering BT, Burm AGL. Spinal anesthesia with
ropivacaine: a double-blind study on the efficacy and safety of
0.5% and 0.75% solutions in patients undergoing minor lower
limb surgery. Anesth Analg 1994;78:1125–30.
7. Feldman HS, Covino BG. Comparative motor-blocking effects
of bupivacaine and ropivacaine, a new amino amide local
anesthetic, in the rat and dog. Anesth Analg 1988;67:1047–52.
8. Chung CJ, Choi SR, Yeo KH, et al. Hyperbaric spinal ropiva-
caine for cesarean delivery: a comparison to hyperbaric bupi-
vacaine. Anesth Analg 2001;93:157–61.
9. Khaw KS, Ngan Kee WD, Wong EL, et al. Spinal ropivacaine
for cesarean section: a dose finding study. Anesthesiology 2001;
95:1346–50.
10. Khaw KS, Ngan Kee WD, Wong M, et al. Spinal ropivacaine
for cesarean delivery: a comparison of hyperbaric and plain
solutions. Anesth Analg 2002;94:680–5.
11. Wahedi W, Nolte H, Klein P. Ropivacaine in spinal anesthesia:
a dose-finding study. Anaesthetist 1996;45:737–44.
12. Gautier PE, De Kock M, Van Steenberge A, et al. Intrathecal
ropivacaine for ambulatory surgery. Anesthesiology 1999;91:
1239–45.
13. McDonald SB, Liu SS, Kopacz DJ, et al. Hyperbaric spinal
ropivacaine: a comparison to bupivacaine in volunteers. Anes-
thesiology 1999;90:971–7.
14. Malinovsky JM, Charles F, Kick O, et al. Intrathecal anesthesia:
ropivacaine versus bupivacaine. Anesth Analg 2000;91:1457–60.
15. Whiteside JB, Burke D, Wildsmith JA. Spinal anaesthesia with
ropivacaine 5 mg ml–1 in glucose 10 mg ml–1 or 50 mg ml–1. Br
J Anaesth 2001;86:241–4.
16. Wong JO, Tan TD, Leung PO, et al. Spinal anesthesia with two
dosages of 0.75% glucose-free ropivacaine: a comparison of
efficacy and safety in Chinese patients undergoing cesarean
section. Acta Anaesthesiol Sin 2003;41:131–8.
Kaohsiung J Med Sci September 2004 • Vol 20 • No 9
J.O.N. Wong, T.D.M. Tan, P.O. Leung, et al
430
± ± – – –
± ± ±
± ± 
± ± ± 
± ± 
